{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 23 of 81', 'Primary variable', 'Change in KCCQ PLS from baseline to week 24.', 'Justification of the design', 'The study is designed to evaluate the safety and efficacy of the 10 mg and of the 15 mg dose', 'regimens of vericiguat at 24 weeks in separate parallel arms. Placebo control is used in a', 'parallel comparator arm to control for observer and patient bias, and randomization to control', 'for assignment bias.', 'Rationale of study endpoints', 'To demonstrate durability of efficacy in improving physical functioning and to study safety', 'beyond the previously studied time period of 12 weeks in SOCRATES-PRESERVED, longer', 'treatment duration of 24 weeks has been chosen for this study. This endpoint gives a valid and', 'appropriate measure of the limitations in activities of daily living that are impacted by HF', 'symptoms of breathlessness and fatigue, and represent the key burden of patients suffering', 'from HFpEF. In SOCRATES-PRESERVED in the 10 mg arm a constant rise in KCCQ PLS', 'that did not yet reach a maximum by week 12 was observed. This was opposed to a smaller', 'improvement in placebo that reached its peak at 8 weeks and subsequently decreased. Based', 'on the exploratory finding of a clinically meaningful improvement in KCCQ PLS (i.e. an', 'improvement compared to placebo larger than 5 points upon 12 weeks treatment with a 10 mg', 'target dose regimen) consistent with parallel improvements in EQ-5D-5L in SOCRATES-', 'PRESERVED, the change in KCCQ PLS from baseline to week 24 is defined as the primary', 'endpoint in the present study. This endpoint will serve for confirmatory testing of the', 'hypothesis that vericiguat improves KCCQ PLS compared to placebo on top of background', 'standard of care in a durable manner upon 24 weeks of treatment. Notably, the parallel', 'ongoing event-driven HFrEF outcome trial VICTORIA plans median treatment duration of 18', 'months to add long-term safety and tolerability data of the 10 mg target dose in HFrEF.', 'End of study', 'The end of the study as a whole will be reached as soon as the last visit of the last patient has', 'been reached in all centers in all participating countries (EU and non-EU).', 'Primary completion', 'The primary completion event for this study is last patient last treatment.', 'The primary completion date for this study according to the FDA Amendment Act is specified', 'in a separate document (not part of this study protocol).', '6.', 'Study population', '6.1', 'Inclusion criteria', '1. Provided written informed consent', '2. Aged 45 years and older', '3. Previous history of chronic HF', '4. HF decompensation within 6 months prior to randomization, defined as hospitalization', 'for HF or IV diuretic treatment for HF without hospitalization.']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 24 of 81', '5. NT-proBNP >300 or BNP >100 pg/mL in sinus rhythm, or NT-proBNP >600 or BNP', '>200 pg/mL in atrial fibrillation within 30 days prior to randomization.', 'The most appropriate natriuretic peptide level cut-off should be guided by the', \"investigator's judgment of the impact of the heart rhythm at the time of blood draw on\", 'natriuretic peptide levels.', '6. Diagnostic criteria of HFpEF by echocardiography assessed within 12 months prior to', 'randomization (most recent measurement must be used to determine eligibility with no', 'interim event signaling potential deterioration in ejection fraction)', 'LVEF >45% and', 'Structural changes indicated by at least one of the following parameters:', 'LV hypertrophy (any of the following: intraventricular septal or', 'posterior wall thickness >1.1 cm, and/or LV mass index >115 g/m\u00b2 in', 'male and >95 g/m\u00b2 in female), or', 'LA enlargement (any of the following: LAV index >29 ml/m\u00b2, or LAV', '>58 mL in male and >52 mL in female patients, or LA area >20 cm\u00b2, or', 'LA diameter >40 mm in male and >38 mm in female patients)', '7. NYHA class II or III at randomization', '8. Men or women', 'Women of childbearing potential can only be included in the study if a', 'pregnancy test is negative and if they agree to use acceptable effective', 'contraception when sexually active. This applies for the time period between', 'signing of the informed consent form and time point after the last', 'administration of study drug. The definition of acceptable effective', 'contraception will be based on the judgment of the investigator and on local', 'requirements.', 'Women are considered post-menopausal and/or not of childbearing potential if', 'they have had 12 months of natural (spontaneous) amenorrhea with an', 'appropriate clinical profile (e.g. age appropriate, history of vasomotor', 'symptoms) or 6 months of spontaneous amenorrhea with serum FSH levels', '>40 mIU/mL [for US only: and estradiol <20 pg/mL] or have had surgical', 'treatment such as bilateral tubal ligation, bilateral ovariectomy, or', 'hysterectomy', '6.2', 'Exclusion criteria', '1. Clinical instability at randomization, defined by any of the following:', 'Any IV treatment including IV diuretics or IV fluids within 24h prior to', 'randomization', 'SBP >160 mmHg', 'SBP <110 mmHg and/or DBP <40 mmHg and/or symptomatic hypotension', 'Resting HR <50 or >100 bpm', '2. Use of IV inotropes at any time between qualifying HF event and randomization', '3. Previous diagnosis of reduced EF (EF <40%)']\n\n###\n\n", "completion": "END"}